The transaction increased German based biopharmaceutical company Heidelberg Pharma AG’s share capital by approximately 10%, with the 3,106,637 newly issued shares offered to qualified institutional investors in Europe and the United States in an accelerated book-building process. At a subscription price of EUR 6.44 per share, the company raised gross proceeds of EUR 20 million.
The new shares were admitted to trading on the Frankfurt Stock Exchange on June 21, 2021.
Pinsent Masons advised Bryan, Garnier & Co, the sole global coordinator and sole bookrunner for the transaction. Bryan, Garnier & Co is one of the most active investment banks in the European growth sector, with a particular focus on healthcare, technology, consumer goods and business services. They are a fully registered broker-dealer, licensed and supervised by the FCA in Europe and FINRA in the US.
The Pinsent Masons team was led by Dr Susanne Lenz, LL.M. and included Roberta Markovina (Partner, London), Dušan Stojković (Senior Associate, Frankfurt) and Sara Šepac (Associate, Frankfurt).
Commenting on the transaction, Dr Susanne Lenz said:
"We are pleased to have worked with Bryan Garnier on this exciting and important transaction. With Heidelberg Pharma AG’s expertise in oncology, we are proud to have been part of the successful financing of a company on the cutting edge of biopharmaceutical research and development in Germany."